Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥344.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥172.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥65.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥29.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥65.3bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥29.3bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥1.66Tat 2022-09-30Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.37Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥904.0bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥904.0bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥202.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥66.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥40.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥25.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥66.112021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥29.222021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥66.072021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥29.22021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥124m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥1.8bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥58.2bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥11.8bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥194.3bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥50.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥92.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥344.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥76.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 696
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_CapitalSurplusIFRSMember51923000000JPY
Equity IFRSCurrentQuarterInstant_TreasurySharesIFRSMember-20428000000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember876498000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember224395000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember1171105000000JPY
Equity IFRSCurrentQuarterInstant1171105000000JPY
Profit loss before tax IFRSPrior1YTDDuration65282000000JPY
Profit loss before tax IFRSCurrentYTDDuration54624000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration28390000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration34357000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration－JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration5280000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-326000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration303000000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSPrior1YTDDuration-1228000000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSCurrentYTDDuration-430000000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-336000000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-532000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration738000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration1308000000JPY
Foreign exchange loss gain ope cf IFRSPrior1YTDDuration389000000JPY
Foreign exchange loss gain ope cf IFRSCurrentYTDDuration3749000000JPY
Loss gain on sale and retirement of fixed assets ope cf IFRSPrior1YTDDuration79000000JPY
Loss gain on sale and retirement of fixed assets ope cf IFRSCurrentYTDDuration-192000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration2828000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration2465000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-3880000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-13328000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-5089000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration-1451000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-3209000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-12262000000JPY
Subtotal ope cf IFRSPrior1YTDDuration83636000000JPY
Subtotal ope cf IFRSCurrentYTDDuration73893000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration615000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration1200000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-713000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-766000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-16804000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-13980000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration66735000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration60346000000JPY
Payments into time deposits inv cf IFRSPrior1YTDDuration-0JPY
Payments into time deposits inv cf IFRSCurrentYTDDuration-175000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YTDDuration1000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYTDDuration0JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-27897000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-24631000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration1000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration430000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass